论文部分内容阅读
[目的]探讨尿吡啶酚(uPyd)、尿脱氧吡啶酚(uDpd)、尿氨基末端肽(uNTx)在肿瘤骨转移患者随访中的应用价值。[方法]晚期肿瘤骨转移患者46例,分别按肿瘤内科治疗原则选用化疗、双膦酸盐治疗、姑息治疗。治疗开始前测定基线uPyd、uDpd、uNTx水平,以后于第1、3个月及以后每3个月检测。记录骨相关不良事件(SRE)。[结果]在1年随访期间,骨转移患者uPyd、uDpd、uNTx水平在含双膦酸盐治疗后1个月有明显下降(P<0.01)。SRE发生时uNTx测定水平与SRE发生前最近一次uNTx测定水平比较有统计学差异(P<0.01),Lg(uNTx/Cr)从2.24±0.12升至2.31±0.13。[结论]uPyd、uDpd、uNTx水平能及时反映抗骨转移治疗特别是双膦酸盐治疗的效果;uNTx水平在SRE发生时有升高趋势,能提示骨病变的进展。
[Objective] To investigate the value of uPyd, uDpd and uNTx in the follow-up of patients with bone metastasis. [Methods] 46 patients with advanced bone metastasis were treated with chemotherapy, bisphosphonate and palliative treatment according to the principle of oncology. Baseline uPyd, uDpd, uNTx levels were measured before treatment was started, and later at 3 and 3 months after the first and third months. Bone-related adverse events (SREs) were recorded. [Results] The levels of uPyd, uDpd and uNTx in patients with bone metastases decreased significantly at 1 month after treatment with bisphosphonates (P <0.01). There was a significant difference between the uNTx level and the most recent uNTx level before SRE (P <0.01). Lg (uNTx / Cr) increased from 2.24 ± 0.12 to 2.31 ± 0.13. [Conclusion] uPyd, uDpd and uNTx levels can reflect the effect of anti-bone metastasis therapy, especially bisphosphonate treatment in a timely manner. The uNTx level is increasing when SRE occurs, which can indicate the progress of bone disease.